Peter Button

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Yung‐Jue Bang, Young‐Woo Kim, Han‐Kwang Yang et al. · The Lancet · 2012 · 1.7K citations

Medicine, Oncology, Surgery +16

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

Patrick Marcellin, George Lau, Ferruccio Bonino et al. · New England Journal of Medicine · 2004 · 1.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

Michael Fried, Teerha Piratvisuth, George Lau et al. · Hepatology · 2008 · 236 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

Keunchil Park, Chong‐Jen Yu, Sang-We Kim et al. · JAMA Oncology · 2015 · 230 citations

Medicine, Oncology, Pharmacology +13

Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in <i>HER2</i>-Positive Metastatic Breast Cancer

Andrew Wardley, Xavier Pivot, Flavia Morales-Vásquez et al. · Journal of Clinical Oncology · 2009 · 118 citations · Full text

Medicine, Oncology, Pharmacotherapy +17